

# Puma Biotechnology

## Earnings Call

### Commercial Update



**August 4, 2022**

**nerlynx<sup>®</sup>**  
(neratinib) tablets




## Forward-Looking Safe-Harbor Statement


*This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.*



# PUMA's Pharmacy and Distributor Network




# ~\$51 Million net NERLYNX revenue in Q2'22




# 3,200 Ex-factory bottles were sold in Q2'22

Bottles Sold (SP + SD) by Quarter



Includes Commercial SP and SD

# ~65% of patients in Q2'22 started at a reduced dose\* \*\*



\*Reduced dose defined as fewer than 6 pills per day

\*\* FDA approved dose-escalation label supplement in June 2021

# Rest of World Partnerships – Timelines

Region	Partner	Regulatory Approvals	Commercial Launches
Australia / SE Asia	 Specialised Therapeutics	<ul style="list-style-type: none"> <li>• 2019 – Ext. Adj. in Australia, Singapore</li> <li>• 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand</li> <li>• <b>Q2 2022 – Ext. Adj. in the Philippines</b></li> </ul>	<ul style="list-style-type: none"> <li>• 2020 – Singapore</li> <li>• Q2 2021 – Malaysia</li> <li>• Q3 / Q4 2021 – Brunei, New Zealand</li> </ul>
Israel	 MEDISON Driving Innovative Healthcare	<ul style="list-style-type: none"> <li>• 2020 – Approved in Ext. Adj. and mBC</li> </ul>	<ul style="list-style-type: none"> <li>• 2020 – Launched</li> </ul>
Canada	 Knight	<ul style="list-style-type: none"> <li>• 2019 – Ext. Adj. approved</li> <li>• Q2 2021 – mBC approved</li> </ul>	<ul style="list-style-type: none"> <li>• 2020 – Launched</li> </ul>
Latin America	 PINT PHARMA	<ul style="list-style-type: none"> <li>• 2019 – Ext Adj in Argentina</li> <li>• 2020 – Ext. Adj in Chile, Ecuador</li> <li>• 2020 – mBC in Argentina</li> <li>• 2021 – Ext Adj and mBC in Peru; mBC in Chile</li> <li>• Q4 2021 – Ext. Adj. in Brazil</li> <li>• Q1 2022 – Ext. Adj. in Mexico</li> <li>• <b>Q3 2022 – mBC in Ecuador</b></li> </ul>	<ul style="list-style-type: none"> <li>• 2020 – Argentina</li> <li>• Q2 2021 – Chile</li> <li>• Q4 2021 – Peru</li> </ul>
Europe Greater China Middle East North and West Africa South Africa Turkey	 Pierre Fabre	<ul style="list-style-type: none"> <li>• 2019 – EMA approval</li> <li>• 2019 – Ext. Adj. in Hong Kong</li> <li>• 2020 – Ext. Adj. in China, Taiwan</li> <li>• Q4 2021 – mBC in Taiwan</li> </ul>	<ul style="list-style-type: none"> <li>• 2019 – Germany, UK, Austria</li> <li>• 2020 – Sweden, Finland, Scotland, Switzerland, Denmark</li> <li>• 2020 – Hong Kong</li> <li>• Q1 2021 – China (added to 2021 NRDL), Taiwan</li> <li>• Q1 2021 – Greece, Czech Republic</li> <li>• Q1 2022 – Ireland</li> <li>• <b>Q3 2022 – Spain</b></li> </ul>
South Korea	 BIXINK THERAPEUTICS	<ul style="list-style-type: none"> <li>• Q4 2021 – Ext. Adj. in S. Korea</li> </ul>	<ul style="list-style-type: none"> <li>• Q1 2022 – Launched</li> </ul>

# Puma Biotechnology

## Earnings Call

### Commercial Update



**August 4, 2022**

**nerlynx<sup>®</sup>**  
(neratinib) tablets

